BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» Astrazeneca woos Lilly to $500M alliance to develop AD BACE inhibitor
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Astrazeneca woos Lilly to $500M alliance to develop AD BACE inhibitor
Sep. 17, 2014
By
Marie Powers
No Comments
Eli Lilly and Co. stepped into the leading role in another effort to develop an oral beta secretase cleaving enzyme (BACE) inhibitor in Alzheimer's disease (AD), this time with fellow pharma Astrazeneca plc.
BioWorld